SlideShare ist ein Scribd-Unternehmen logo
1 von 45
Downloaden Sie, um offline zu lesen
Dr Naina Kumar
SR 1 Surgical oncology, SMS Hospital Jaipur
Management of Renal Cell
Carcinomas
31.08.21
Renal cell carcinoma: MAnagement guidelines
Renal cell carcinoma: MAnagement guidelines
Genetic syndromes and RCC :
Management
Renal cell carcinoma: MAnagement guidelines
Renal cell carcinoma: MAnagement guidelines
HEREDITARY KIDNEY CANCER SYNDROMES, GENETICS, AND
MOLECULAR BIOLOGY Management:
• Management of renal tumors in patients with VHL now includes surveillance of
smaller tumors (<3 cm) and resection of larger ones (>3 cm) by PN with the goal of
preventing metastases and optimizing renal function by “resetting the biologic clock”
through appropriately timed surgeries.
• The goal of complete tumor removal with wide negative surgical margins is less
appropriate for these patients, where management of localized lesions supplants cure.
HPRCC:
• As with VHL, management of renal tumors recognizes the need to remove larger
lesions and observe smaller ones.
• Although no size cutoff for intervention has been established, the biology of type 1
papillary RCC appears to be more indolent than ccRCC, suggesting the risk of death
from kidney cancer in these patients is low.
• Unfortunately, renal mass biopsy cannot reliably make a diagnosis of type 1 papillary
RCC, so surgery is sometimes required.
• As such, PN with renal preservation is emphasized despite the often encountered
diffuse micro- and macromultifocality of these lesions.
Hereditary Leiomyomatosis Renal Cell Carcinoma:
• Unlike other hereditary forms of RCC, AS with delayed intervention for small tumors
is not recommended due to the aggressive nature of these tumors. Although tumor
enucleation is recommended for most patients with hereditary tumors, renal lesions
associated with this syndrome tend to be infiltrative, thus wide local excision is
recommended at initial diagnosis, even for tumors <3 cm.
Renal cell carcinoma: MAnagement guidelines
Staging and Prognosis:
Renal cell carcinoma: MAnagement guidelines
Renal cell carcinoma: MAnagement guidelines
TREATMENT OF LOCALIZED
RENAL CELL CARCINOMA
Renal cell carcinoma: MAnagement guidelines
Renal cell carcinoma: MAnagement guidelines
Renal cell carcinoma: MAnagement guidelines
Renal cell carcinoma: MAnagement guidelines
Radical Nephrectomy for Renal
Cell Carcinoma
• RN” as currently practiced may be better termed “total” nephrectomy, as it often omits
several of the components of the original, “radical” nephrectomy, which always included
extrafascial nephrectomy, adrenalectomy, and extended lymphadenectomy (LND) from
the crus of the diaphragm to the aortic bifurcation.
• Perifascial dissection is still routinely practiced for larger tumors, as ≥25% of these
tumors extend into the perinephric fat.
• Removal of the ipsilateral adrenal gland is no longer recommended, unless there is
suspicion of direct invasion of the gland by tumor or a radiographically or clinically
suspicious adrenal tumor because of the similar propensity of RCC to metastasize to the
ipsilateral or contralateral adrenal gland.
• Finally, extended LND has been shown to be of no therapeutic benefit for patients with clinically
localized RCC as the risks of clinically negative nodes being pathologically involved is <5%.46
The role of LND in high-risk (>pT2 N+ M+) renal tumors remains controversial.
• RN is still a preferred option for some patients with localized RCC, such as those with very large
tumors (most clinical T2 tumors) or the relatively limited subgroup of patients with clinical T1
tumors that are not amenable to nephron-sparing approaches.
• According to the 2017 AUA guidelines, physicians should consider RN for patients with a solid
or Bosniak 3/4 complex cystic renal mass where increased oncologic potential is suggested by
tumor size, renal mass biopsy, and/or imaging characteristics and in whom active treatment is
planned.
• In this setting, RN is preferred if all of the following criteria are met:
• (1) high tumor complexity and PN would be challenging even in experienced hands;
• (2) no preexisting chronic kidney disease (CKD) or proteinuria; and
• (3) normal contralateral kidney and new baseline estimated glomerular filtration rate (eGFR)
will likely be >45 mL/min/1.73 m2
• The surgical approach for RN depends on the size and location of the tumor as well as the
patient’s habitus and medical/surgical history. For locally advanced disease and/or bulky
lymphadenopathy, an open surgical approach using either an extended subcostal, midline, or
thoracoabdominal incision is generally used.
• Current minimally invasive approaches allow all of the essential steps of RN to be
performed, with the associated benefits of shorter convalescence and reduced morbidity.
• Laparoscopic RN is now established as a preferred approach for moderate to large
volume tumors (≤10 to 12 cm), without invasion of adjacent organs, with limited (or no)
venous involvement, and having manageable (or no) lymphadenopathy.
• Robotic RN may further extend the indications for minimally invasive radical
nephrectomy (MIRN), to include some patients with features previously thought to
mandate open RN as vascular control and suturing is facilitated with this approach.
Important pointers
Renal cell carcinoma: MAnagement guidelines
Renal cell carcinoma: MAnagement guidelines
Metastatic disease stage IV:
Renal cell carcinoma: MAnagement guidelines
Opinion from UpToDate:
Is there a role for adjuvant therapy? — For patients with localized clear cell renal
carcinoma treated with nephrectomy, adjuvant pembrolizumab improved disease-free
survival (DFS) and was well tolerated in a phase III trial. These data are promising, and
we await regulatory approval and/or introduction into consensus guidelines prior to
incorporating adjuvant immunotherapy into routine clinical practice.
We also do not suggest the use of adjuvant sunitinib. Although adjuvant sunitinib
improved DFS in select patients with high-risk disease in one clinical trial, it confers no
clear overall survival (OS) benefit and increases toxicity.
Other trials evaluating sunitinib and sorafenib (ASSURE and SORCE), pazopanib
(PROTECT), and axitinib (ATLAS) have failed to demonstrate a recurrence-free or OS
benefit in the adjuvant setting.
●
Everolimus – A randomized clinical trial (EVEREST) is ongoing evaluating mechanistic
(mammalian) target of rapamycin (mTOR) inhibitor everolimus as adjuvant therapy
(NCT01120249).
Renal cell carcinoma: MAnagement guidelines
Risk stratification :
Renal cell carcinoma: MAnagement guidelines
Renal cell carcinoma: MAnagement guidelines
Renal cell carcinoma: MAnagement guidelines
Renal cell carcinoma: MAnagement guidelines
Renal cell carcinoma: MAnagement guidelines
Renal cell carcinoma: MAnagement guidelines
Renal cell carcinoma: MAnagement guidelines
Renal cell carcinoma: MAnagement guidelines
Renal cell carcinoma: MAnagement guidelines
Renal cell carcinoma: MAnagement guidelines
Follow up
Renal cell carcinoma: MAnagement guidelines
Thank you!

Weitere ähnliche Inhalte

Was ist angesagt?

Renal cell carcinoma
Renal cell carcinomaRenal cell carcinoma
Renal cell carcinomaRobal Lacoul
 
Renal Cell Carcinoma Treatment
Renal Cell Carcinoma TreatmentRenal Cell Carcinoma Treatment
Renal Cell Carcinoma Treatmentibrahimkiwan1
 
Management of renal cell carcinoma - presented at Asian Oncology Summit 2013
Management of renal cell carcinoma - presented at Asian Oncology Summit 2013Management of renal cell carcinoma - presented at Asian Oncology Summit 2013
Management of renal cell carcinoma - presented at Asian Oncology Summit 2013Siewhong Ho
 
MANAGEMENT OF HEPATOCELLULAR CARCINOMA
MANAGEMENT OF HEPATOCELLULAR CARCINOMAMANAGEMENT OF HEPATOCELLULAR CARCINOMA
MANAGEMENT OF HEPATOCELLULAR CARCINOMAIsha Jaiswal
 
Renal Cancers Rationale
Renal Cancers RationaleRenal Cancers Rationale
Renal Cancers Rationalefondas vakalis
 
Metastatic colorectal liver cancer
Metastatic colorectal liver cancerMetastatic colorectal liver cancer
Metastatic colorectal liver cancerBashir BnYunus
 
Renal cell carcinoma. 2015
Renal cell carcinoma. 2015Renal cell carcinoma. 2015
Renal cell carcinoma. 2015Montse Carrere
 
Muscle invasive bladder cancer
Muscle invasive bladder cancerMuscle invasive bladder cancer
Muscle invasive bladder cancerdrswati2002
 
Case presentation (metastatic rcc)
Case presentation (metastatic rcc)Case presentation (metastatic rcc)
Case presentation (metastatic rcc)Dr./ Ihab Samy
 
Renal Cancers Rationale
Renal Cancers RationaleRenal Cancers Rationale
Renal Cancers Rationalefondas vakalis
 
Prostate carcinoma- etiopathogenesis
Prostate  carcinoma- etiopathogenesisProstate  carcinoma- etiopathogenesis
Prostate carcinoma- etiopathogenesisGovtRoyapettahHospit
 
Hepatocellular carcinoma—role of interventional radiologist Dr. Muhammad Bin ...
Hepatocellular carcinoma—role of interventional radiologist Dr. Muhammad Bin ...Hepatocellular carcinoma—role of interventional radiologist Dr. Muhammad Bin ...
Hepatocellular carcinoma—role of interventional radiologist Dr. Muhammad Bin ...Dr. Muhammad Bin Zulfiqar
 

Was ist angesagt? (20)

Rcc by dr shiv
Rcc by dr shivRcc by dr shiv
Rcc by dr shiv
 
Rcc by ramu
Rcc by ramuRcc by ramu
Rcc by ramu
 
Role of surgery in testicular cancer
Role of surgery in testicular cancerRole of surgery in testicular cancer
Role of surgery in testicular cancer
 
Renal cell carcinoma
Renal cell carcinomaRenal cell carcinoma
Renal cell carcinoma
 
Renal Cell Carcinoma Treatment
Renal Cell Carcinoma TreatmentRenal Cell Carcinoma Treatment
Renal Cell Carcinoma Treatment
 
Renal cell carcinoma
Renal cell carcinomaRenal cell carcinoma
Renal cell carcinoma
 
Management of renal cell carcinoma - presented at Asian Oncology Summit 2013
Management of renal cell carcinoma - presented at Asian Oncology Summit 2013Management of renal cell carcinoma - presented at Asian Oncology Summit 2013
Management of renal cell carcinoma - presented at Asian Oncology Summit 2013
 
HCC premanagment
HCC  premanagmentHCC  premanagment
HCC premanagment
 
MANAGEMENT OF HEPATOCELLULAR CARCINOMA
MANAGEMENT OF HEPATOCELLULAR CARCINOMAMANAGEMENT OF HEPATOCELLULAR CARCINOMA
MANAGEMENT OF HEPATOCELLULAR CARCINOMA
 
Renal Cancers Rationale
Renal Cancers RationaleRenal Cancers Rationale
Renal Cancers Rationale
 
imaging in RCC
imaging in RCCimaging in RCC
imaging in RCC
 
Srm
SrmSrm
Srm
 
Metastatic colorectal liver cancer
Metastatic colorectal liver cancerMetastatic colorectal liver cancer
Metastatic colorectal liver cancer
 
Wilms tumor
Wilms tumorWilms tumor
Wilms tumor
 
Renal cell carcinoma. 2015
Renal cell carcinoma. 2015Renal cell carcinoma. 2015
Renal cell carcinoma. 2015
 
Muscle invasive bladder cancer
Muscle invasive bladder cancerMuscle invasive bladder cancer
Muscle invasive bladder cancer
 
Case presentation (metastatic rcc)
Case presentation (metastatic rcc)Case presentation (metastatic rcc)
Case presentation (metastatic rcc)
 
Renal Cancers Rationale
Renal Cancers RationaleRenal Cancers Rationale
Renal Cancers Rationale
 
Prostate carcinoma- etiopathogenesis
Prostate  carcinoma- etiopathogenesisProstate  carcinoma- etiopathogenesis
Prostate carcinoma- etiopathogenesis
 
Hepatocellular carcinoma—role of interventional radiologist Dr. Muhammad Bin ...
Hepatocellular carcinoma—role of interventional radiologist Dr. Muhammad Bin ...Hepatocellular carcinoma—role of interventional radiologist Dr. Muhammad Bin ...
Hepatocellular carcinoma—role of interventional radiologist Dr. Muhammad Bin ...
 

Ähnlich wie Renal cell carcinoma: MAnagement guidelines

Management of Renal Cell Carcinoma ppt.pptx
Management of Renal Cell Carcinoma ppt.pptxManagement of Renal Cell Carcinoma ppt.pptx
Management of Renal Cell Carcinoma ppt.pptxAtulGupta369
 
Bevacizumab plus m folfox6 versus mfolfox6 alone as first line
Bevacizumab plus m folfox6 versus mfolfox6 alone as first lineBevacizumab plus m folfox6 versus mfolfox6 alone as first line
Bevacizumab plus m folfox6 versus mfolfox6 alone as first lineKishore Chandra Korada
 
ROLE OF DIAGNOSTIC LAPROSCOPY IN ABDOMINAL MALIGNANCIES.pptx
ROLE OF DIAGNOSTIC LAPROSCOPY IN ABDOMINAL MALIGNANCIES.pptxROLE OF DIAGNOSTIC LAPROSCOPY IN ABDOMINAL MALIGNANCIES.pptx
ROLE OF DIAGNOSTIC LAPROSCOPY IN ABDOMINAL MALIGNANCIES.pptxparikshithm1
 
RCC- Staging and treatment of Renal Cell Carcinoma
RCC- Staging and treatment of Renal Cell CarcinomaRCC- Staging and treatment of Renal Cell Carcinoma
RCC- Staging and treatment of Renal Cell CarcinomaBe Akash Sah
 
Laparoscopic Partial Nephrectomy of Hilar Tumors with Cold Ischemia
Laparoscopic Partial Nephrectomy of Hilar Tumors with Cold IschemiaLaparoscopic Partial Nephrectomy of Hilar Tumors with Cold Ischemia
Laparoscopic Partial Nephrectomy of Hilar Tumors with Cold Ischemiaguestd58ac53
 
Management of patients with primary colorectal cancer and
Management of patients with primary colorectal cancer andManagement of patients with primary colorectal cancer and
Management of patients with primary colorectal cancer andYuvaraj Karthick
 
Intraoperative diagnosis of perhilar cholangiocarcinoma
Intraoperative diagnosis of perhilar cholangiocarcinomaIntraoperative diagnosis of perhilar cholangiocarcinoma
Intraoperative diagnosis of perhilar cholangiocarcinomaGian Luca Grazi
 
Rectal Adenocarcinoma Guidelines.pptx
Rectal Adenocarcinoma Guidelines.pptxRectal Adenocarcinoma Guidelines.pptx
Rectal Adenocarcinoma Guidelines.pptxMuneebaBinteSaeed1
 
Highlights in the treatment of Rectal cancer.pptx
Highlights in the treatment of Rectal cancer.pptxHighlights in the treatment of Rectal cancer.pptx
Highlights in the treatment of Rectal cancer.pptxMona Quenawy
 
Management Guideline in Colorectal Cancer.pptx
Management Guideline in Colorectal Cancer.pptxManagement Guideline in Colorectal Cancer.pptx
Management Guideline in Colorectal Cancer.pptxAtulGupta369
 
PPT.pptxfhj iytd jhjkj hgf uykjjn khgyfu iuf tyyf uyu v ctrc67 v ciytr57i
PPT.pptxfhj iytd jhjkj  hgf uykjjn khgyfu  iuf tyyf uyu v ctrc67 v ciytr57iPPT.pptxfhj iytd jhjkj  hgf uykjjn khgyfu  iuf tyyf uyu v ctrc67 v ciytr57i
PPT.pptxfhj iytd jhjkj hgf uykjjn khgyfu iuf tyyf uyu v ctrc67 v ciytr57ikishansuyal
 

Ähnlich wie Renal cell carcinoma: MAnagement guidelines (20)

Management of Renal Cell Carcinoma ppt.pptx
Management of Renal Cell Carcinoma ppt.pptxManagement of Renal Cell Carcinoma ppt.pptx
Management of Renal Cell Carcinoma ppt.pptx
 
bclc.pptx
bclc.pptxbclc.pptx
bclc.pptx
 
SMALL RENAL MASS
SMALL RENAL MASSSMALL RENAL MASS
SMALL RENAL MASS
 
Bevacizumab plus m folfox6 versus mfolfox6 alone as first line
Bevacizumab plus m folfox6 versus mfolfox6 alone as first lineBevacizumab plus m folfox6 versus mfolfox6 alone as first line
Bevacizumab plus m folfox6 versus mfolfox6 alone as first line
 
Cystic neoplasm of pancrease dr mnr
Cystic neoplasm of pancrease dr mnrCystic neoplasm of pancrease dr mnr
Cystic neoplasm of pancrease dr mnr
 
ROLE OF DIAGNOSTIC LAPROSCOPY IN ABDOMINAL MALIGNANCIES.pptx
ROLE OF DIAGNOSTIC LAPROSCOPY IN ABDOMINAL MALIGNANCIES.pptxROLE OF DIAGNOSTIC LAPROSCOPY IN ABDOMINAL MALIGNANCIES.pptx
ROLE OF DIAGNOSTIC LAPROSCOPY IN ABDOMINAL MALIGNANCIES.pptx
 
Rni pp
Rni   ppRni   pp
Rni pp
 
Mangment of recurent sarcoma
Mangment of recurent sarcomaMangment of recurent sarcoma
Mangment of recurent sarcoma
 
RCC- Staging and treatment of Renal Cell Carcinoma
RCC- Staging and treatment of Renal Cell CarcinomaRCC- Staging and treatment of Renal Cell Carcinoma
RCC- Staging and treatment of Renal Cell Carcinoma
 
Oncology basics
Oncology basicsOncology basics
Oncology basics
 
Laparoscopic Partial Nephrectomy of Hilar Tumors with Cold Ischemia
Laparoscopic Partial Nephrectomy of Hilar Tumors with Cold IschemiaLaparoscopic Partial Nephrectomy of Hilar Tumors with Cold Ischemia
Laparoscopic Partial Nephrectomy of Hilar Tumors with Cold Ischemia
 
HCC MANGEMENT(RAD ONCO)
HCC MANGEMENT(RAD ONCO)HCC MANGEMENT(RAD ONCO)
HCC MANGEMENT(RAD ONCO)
 
Rectal Carcinoma
Rectal CarcinomaRectal Carcinoma
Rectal Carcinoma
 
Management of patients with primary colorectal cancer and
Management of patients with primary colorectal cancer andManagement of patients with primary colorectal cancer and
Management of patients with primary colorectal cancer and
 
Intraoperative diagnosis of perhilar cholangiocarcinoma
Intraoperative diagnosis of perhilar cholangiocarcinomaIntraoperative diagnosis of perhilar cholangiocarcinoma
Intraoperative diagnosis of perhilar cholangiocarcinoma
 
Rectal Adenocarcinoma Guidelines.pptx
Rectal Adenocarcinoma Guidelines.pptxRectal Adenocarcinoma Guidelines.pptx
Rectal Adenocarcinoma Guidelines.pptx
 
Retroperitoneal soft tissue sarcomas (rps)
Retroperitoneal soft tissue sarcomas (rps)Retroperitoneal soft tissue sarcomas (rps)
Retroperitoneal soft tissue sarcomas (rps)
 
Highlights in the treatment of Rectal cancer.pptx
Highlights in the treatment of Rectal cancer.pptxHighlights in the treatment of Rectal cancer.pptx
Highlights in the treatment of Rectal cancer.pptx
 
Management Guideline in Colorectal Cancer.pptx
Management Guideline in Colorectal Cancer.pptxManagement Guideline in Colorectal Cancer.pptx
Management Guideline in Colorectal Cancer.pptx
 
PPT.pptxfhj iytd jhjkj hgf uykjjn khgyfu iuf tyyf uyu v ctrc67 v ciytr57i
PPT.pptxfhj iytd jhjkj  hgf uykjjn khgyfu  iuf tyyf uyu v ctrc67 v ciytr57iPPT.pptxfhj iytd jhjkj  hgf uykjjn khgyfu  iuf tyyf uyu v ctrc67 v ciytr57i
PPT.pptxfhj iytd jhjkj hgf uykjjn khgyfu iuf tyyf uyu v ctrc67 v ciytr57i
 

Mehr von Dr. Naina Kumar Agarwal

management of locally advanced breast cancer 2022
management of locally advanced breast cancer 2022management of locally advanced breast cancer 2022
management of locally advanced breast cancer 2022Dr. Naina Kumar Agarwal
 
Treatment of oral carcinoms: surgical oncologist
Treatment of oral carcinoms: surgical oncologistTreatment of oral carcinoms: surgical oncologist
Treatment of oral carcinoms: surgical oncologistDr. Naina Kumar Agarwal
 
Carcinoma cervix management : 2022 nccn guidelines
Carcinoma cervix management : 2022 nccn guidelinesCarcinoma cervix management : 2022 nccn guidelines
Carcinoma cervix management : 2022 nccn guidelinesDr. Naina Kumar Agarwal
 
Carcinoma Prostate: etiopathogenesis and staging- 2022 guidelines
Carcinoma Prostate: etiopathogenesis and staging- 2022 guidelinesCarcinoma Prostate: etiopathogenesis and staging- 2022 guidelines
Carcinoma Prostate: etiopathogenesis and staging- 2022 guidelinesDr. Naina Kumar Agarwal
 
Carcinoma anal canal - Dr Naina kumar agarwal MCh surgical oncology resident
Carcinoma anal canal - Dr Naina kumar agarwal MCh surgical oncology residentCarcinoma anal canal - Dr Naina kumar agarwal MCh surgical oncology resident
Carcinoma anal canal - Dr Naina kumar agarwal MCh surgical oncology residentDr. Naina Kumar Agarwal
 
Etiopathogenesis and staging of gastric cancer
Etiopathogenesis and staging of gastric cancerEtiopathogenesis and staging of gastric cancer
Etiopathogenesis and staging of gastric cancerDr. Naina Kumar Agarwal
 

Mehr von Dr. Naina Kumar Agarwal (12)

Prostate cancer guidelines 2023
Prostate cancer guidelines 2023Prostate cancer guidelines 2023
Prostate cancer guidelines 2023
 
management of locally advanced breast cancer 2022
management of locally advanced breast cancer 2022management of locally advanced breast cancer 2022
management of locally advanced breast cancer 2022
 
Treatment of oral carcinoms: surgical oncologist
Treatment of oral carcinoms: surgical oncologistTreatment of oral carcinoms: surgical oncologist
Treatment of oral carcinoms: surgical oncologist
 
Carcinoma cervix management : 2022 nccn guidelines
Carcinoma cervix management : 2022 nccn guidelinesCarcinoma cervix management : 2022 nccn guidelines
Carcinoma cervix management : 2022 nccn guidelines
 
Carcinoma Prostate: etiopathogenesis and staging- 2022 guidelines
Carcinoma Prostate: etiopathogenesis and staging- 2022 guidelinesCarcinoma Prostate: etiopathogenesis and staging- 2022 guidelines
Carcinoma Prostate: etiopathogenesis and staging- 2022 guidelines
 
CHOLANGIOCARCINOMA- BILE DUCT CANCER
CHOLANGIOCARCINOMA- BILE DUCT CANCERCHOLANGIOCARCINOMA- BILE DUCT CANCER
CHOLANGIOCARCINOMA- BILE DUCT CANCER
 
management of carcinoma cervix- 2021
management of carcinoma cervix- 2021management of carcinoma cervix- 2021
management of carcinoma cervix- 2021
 
Carcinoma anal canal - Dr Naina kumar agarwal MCh surgical oncology resident
Carcinoma anal canal - Dr Naina kumar agarwal MCh surgical oncology residentCarcinoma anal canal - Dr Naina kumar agarwal MCh surgical oncology resident
Carcinoma anal canal - Dr Naina kumar agarwal MCh surgical oncology resident
 
Etiopathogenesis and staging of gastric cancer
Etiopathogenesis and staging of gastric cancerEtiopathogenesis and staging of gastric cancer
Etiopathogenesis and staging of gastric cancer
 
Oncogenic viruses
Oncogenic virusesOncogenic viruses
Oncogenic viruses
 
Signalling pathways in tumorigenesis
Signalling pathways in tumorigenesisSignalling pathways in tumorigenesis
Signalling pathways in tumorigenesis
 
Cell cycle and its regulation
Cell cycle and its regulationCell cycle and its regulation
Cell cycle and its regulation
 

Kürzlich hochgeladen

Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .Mohamed Rizk Khodair
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptxNIKITA BHUTE
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptPradnya Wadekar
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfDolisha Warbi
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.kishan singh tomar
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)kishan singh tomar
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectiondrhanifmohdali
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionkrishnareddy157915
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE Mamatha Lakka
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfHongBiThi1
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfMedicoseAcademics
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu Medical University
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondSujoy Dasgupta
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024EwoutSteyerberg1
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfHongBiThi1
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Peter Embi
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisSujoy Dasgupta
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project reportNARMADAPETROLEUMGAS
 
historyofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusanguhistoryofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusangu Medical University
 

Kürzlich hochgeladen (20)

Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.ppt
 
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissection
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung function
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdf
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and Beyond
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosis
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project report
 
historyofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusanguhistoryofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusangu
 

Renal cell carcinoma: MAnagement guidelines

  • 1. Dr Naina Kumar SR 1 Surgical oncology, SMS Hospital Jaipur Management of Renal Cell Carcinomas 31.08.21
  • 4. Genetic syndromes and RCC : Management
  • 7. HEREDITARY KIDNEY CANCER SYNDROMES, GENETICS, AND MOLECULAR BIOLOGY Management: • Management of renal tumors in patients with VHL now includes surveillance of smaller tumors (<3 cm) and resection of larger ones (>3 cm) by PN with the goal of preventing metastases and optimizing renal function by “resetting the biologic clock” through appropriately timed surgeries. • The goal of complete tumor removal with wide negative surgical margins is less appropriate for these patients, where management of localized lesions supplants cure.
  • 8. HPRCC: • As with VHL, management of renal tumors recognizes the need to remove larger lesions and observe smaller ones. • Although no size cutoff for intervention has been established, the biology of type 1 papillary RCC appears to be more indolent than ccRCC, suggesting the risk of death from kidney cancer in these patients is low. • Unfortunately, renal mass biopsy cannot reliably make a diagnosis of type 1 papillary RCC, so surgery is sometimes required. • As such, PN with renal preservation is emphasized despite the often encountered diffuse micro- and macromultifocality of these lesions.
  • 9. Hereditary Leiomyomatosis Renal Cell Carcinoma: • Unlike other hereditary forms of RCC, AS with delayed intervention for small tumors is not recommended due to the aggressive nature of these tumors. Although tumor enucleation is recommended for most patients with hereditary tumors, renal lesions associated with this syndrome tend to be infiltrative, thus wide local excision is recommended at initial diagnosis, even for tumors <3 cm.
  • 19. Radical Nephrectomy for Renal Cell Carcinoma
  • 20. • RN” as currently practiced may be better termed “total” nephrectomy, as it often omits several of the components of the original, “radical” nephrectomy, which always included extrafascial nephrectomy, adrenalectomy, and extended lymphadenectomy (LND) from the crus of the diaphragm to the aortic bifurcation. • Perifascial dissection is still routinely practiced for larger tumors, as ≥25% of these tumors extend into the perinephric fat. • Removal of the ipsilateral adrenal gland is no longer recommended, unless there is suspicion of direct invasion of the gland by tumor or a radiographically or clinically suspicious adrenal tumor because of the similar propensity of RCC to metastasize to the ipsilateral or contralateral adrenal gland.
  • 21. • Finally, extended LND has been shown to be of no therapeutic benefit for patients with clinically localized RCC as the risks of clinically negative nodes being pathologically involved is <5%.46 The role of LND in high-risk (>pT2 N+ M+) renal tumors remains controversial. • RN is still a preferred option for some patients with localized RCC, such as those with very large tumors (most clinical T2 tumors) or the relatively limited subgroup of patients with clinical T1 tumors that are not amenable to nephron-sparing approaches. • According to the 2017 AUA guidelines, physicians should consider RN for patients with a solid or Bosniak 3/4 complex cystic renal mass where increased oncologic potential is suggested by tumor size, renal mass biopsy, and/or imaging characteristics and in whom active treatment is planned.
  • 22. • In this setting, RN is preferred if all of the following criteria are met: • (1) high tumor complexity and PN would be challenging even in experienced hands; • (2) no preexisting chronic kidney disease (CKD) or proteinuria; and • (3) normal contralateral kidney and new baseline estimated glomerular filtration rate (eGFR) will likely be >45 mL/min/1.73 m2 • The surgical approach for RN depends on the size and location of the tumor as well as the patient’s habitus and medical/surgical history. For locally advanced disease and/or bulky lymphadenopathy, an open surgical approach using either an extended subcostal, midline, or thoracoabdominal incision is generally used.
  • 23. • Current minimally invasive approaches allow all of the essential steps of RN to be performed, with the associated benefits of shorter convalescence and reduced morbidity. • Laparoscopic RN is now established as a preferred approach for moderate to large volume tumors (≤10 to 12 cm), without invasion of adjacent organs, with limited (or no) venous involvement, and having manageable (or no) lymphadenopathy. • Robotic RN may further extend the indications for minimally invasive radical nephrectomy (MIRN), to include some patients with features previously thought to mandate open RN as vascular control and suturing is facilitated with this approach.
  • 29. Opinion from UpToDate: Is there a role for adjuvant therapy? — For patients with localized clear cell renal carcinoma treated with nephrectomy, adjuvant pembrolizumab improved disease-free survival (DFS) and was well tolerated in a phase III trial. These data are promising, and we await regulatory approval and/or introduction into consensus guidelines prior to incorporating adjuvant immunotherapy into routine clinical practice. We also do not suggest the use of adjuvant sunitinib. Although adjuvant sunitinib improved DFS in select patients with high-risk disease in one clinical trial, it confers no clear overall survival (OS) benefit and increases toxicity.
  • 30. Other trials evaluating sunitinib and sorafenib (ASSURE and SORCE), pazopanib (PROTECT), and axitinib (ATLAS) have failed to demonstrate a recurrence-free or OS benefit in the adjuvant setting. ● Everolimus – A randomized clinical trial (EVEREST) is ongoing evaluating mechanistic (mammalian) target of rapamycin (mTOR) inhibitor everolimus as adjuvant therapy (NCT01120249).